165 related articles for article (PubMed ID: 35596678)
1. Application of an Environmental Monitoring to Assess the Practices and Control the Risk of Occupational Exposure to Cyclophosphamide in Two Sites of a French Comprehensive Cancer Center.
Acramel A; Fouque J; Blondeel-Gomes S; Huguet S; Rezai K; Madar O; Escalup L
Ann Work Expo Health; 2022 Nov; 66(9):1215-1223. PubMed ID: 35596678
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of external contamination on the vial surfaces of some hazardous drugs that commonly used in Chinese hospitals and comparison between environmental contamination generated during robotic compounding by IV: Dispensing robot vs. manual compounding in biological safety cabinet.
Ml H; T W; Jq Z; Yj S; Tj G; Lk Z; J L; Jf Y
J Oncol Pharm Pract; 2022 Oct; 28(7):1487-1498. PubMed ID: 34162245
[TBL] [Abstract][Full Text] [Related]
3. A case study: surface contamination of cyclophosphamide due to working practices and cleaning procedures in two Italian hospitals.
Acampora A; Castiglia L; Miraglia N; Pieri M; Soave C; Liotti F; Sannolo N
Ann Occup Hyg; 2005 Oct; 49(7):611-8. PubMed ID: 15964876
[TBL] [Abstract][Full Text] [Related]
4. Antineoplastic drug contamination on the hands of employees working throughout the hospital medication system.
Hon CY; Teschke K; Demers PA; Venners S
Ann Occup Hyg; 2014 Jul; 58(6):761-70. PubMed ID: 24644303
[TBL] [Abstract][Full Text] [Related]
5. The assessment of environmental and external cross-contamination in preparing ready-to-administer cytotoxic drugs: a comparison between a robotic system and conventional manual production.
Werumeus Buning A; Geersing TH; Crul M
Int J Pharm Pract; 2020 Feb; 28(1):66-74. PubMed ID: 31489970
[TBL] [Abstract][Full Text] [Related]
6. Pilot assessment of the antineoplastic drug contamination levels in British Columbian hospitals pre- and post-cleaning.
Chu WC; Hon CY; Danyluk Q; Chua PP; Astrakianakis G
J Oncol Pharm Pract; 2012 Mar; 18(1):46-51. PubMed ID: 21737485
[TBL] [Abstract][Full Text] [Related]
7. Antineoplastic drug contamination of surfaces throughout the hospital medication system in Canadian hospitals.
Hon CY; Teschke K; Chu W; Demers P; Venners S
J Occup Environ Hyg; 2013; 10(7):374-83. PubMed ID: 23668810
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the efficacy of additional measures introduced for the protection of healthcare personnel handling antineoplastic drugs.
Odraska P; Dolezalova L; Kuta J; Oravec M; Piler P; Blaha L
Ann Occup Hyg; 2013 Mar; 57(2):240-50. PubMed ID: 22926784
[TBL] [Abstract][Full Text] [Related]
9. A quantitative LC-MS method to determine surface contamination of antineoplastic drugs by wipe sampling.
Kåredal M; Jönsson R; Wetterling M; Björk B; Hedmer M
J Occup Environ Hyg; 2022 Jan; 19(1):50-66. PubMed ID: 34723774
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the efficacy of a self-cleaning automated compounding system for the decontamination of cytotoxic drugs.
Telleria N; García N; Grisaleña J; Algaba N; Bergareche E; Tamés MJ; Cajaraville G
J Oncol Pharm Pract; 2021 Sep; 27(6):1343-1353. PubMed ID: 32854575
[TBL] [Abstract][Full Text] [Related]
11. Occupational exposure to antineoplastic drugs in hospital environments: potential risk associated with contact with cyclophosphamide- and ifosfamide-contaminated surfaces.
Mucci N; Dugheri S; Farioli A; Garzaro G; Rapisarda V; Campagna M; Bonari A; Arcangeli G
Med Pr; 2020 Sep; 71(5):519-529. PubMed ID: 32667290
[TBL] [Abstract][Full Text] [Related]
12. The application of novel field measurement and field evaluation protocols for assessing health care workers' exposure risk to antineoplastic drugs.
Astrakianakis G; Jeronimo M; Griffiths A; Colombo M; Kramer D; Demers PA; Hon CY
J Occup Environ Hyg; 2020 Sep; 17(9):373-382. PubMed ID: 32615872
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Closed-system Transfer Devices in Reducing Potential Risk for Surface Contamination Following Simulated Hazardous-drug Preparation and Compounding.
Soefje S; Rickabaugh K; Rajkumar R; Wall KP
Int J Pharm Compd; 2022; 26(1):72-79. PubMed ID: 35081047
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Closed-system Transfer Devices in Reducing Potential Risk for Surface Contamination Following Simulated Hazardous-drug Preparation and Compounding.
Soefje S; Rickabaugh K; Rajkumar R; Wall KP
Int J Pharm Compd; 2021; 25(6):515-522. PubMed ID: 34807847
[TBL] [Abstract][Full Text] [Related]
15. Wipe Sampling Method and Evaluation of Environmental Variables for Assessing Surface Contamination of 10 Antineoplastic Drugs by Liquid Chromatography/Tandem Mass Spectrometry.
Colombo M; Jeronimo M; Astrakianakis G; Apte C; Hon CY
Ann Work Expo Health; 2017 Oct; 61(8):1003-1014. PubMed ID: 29028255
[TBL] [Abstract][Full Text] [Related]
16. Spatial and Temporal Variability in Antineoplastic Drug Surface Contamination in Cancer Care Centers in Alberta and Minnesota.
Jeronimo M; Arnold S; Astrakianakis G; Lyden G; Stewart Q; Petersen A; Chambers C; Malard Johnson D; Zimdars E; Kaup H; Davies HW
Ann Work Expo Health; 2021 Aug; 65(7):760-774. PubMed ID: 33889938
[TBL] [Abstract][Full Text] [Related]
17. Residual contamination in antineoplastic drug packaging.
E Silva LS; Machado CDSB; Linden R; Antunes MV; da Silva LC; Wayhs CAY; Capp E; Ness SLR
J Oncol Pharm Pract; 2023 Dec; 29(8):1862-1867. PubMed ID: 36659825
[TBL] [Abstract][Full Text] [Related]
18. Occupational exposure to antineoplastic drugs: what about hospital sanitation personnel?
Labrèche F; Ouellet C; Roberge B; Caron NJ; Yennek A; Bussières JF
Int Arch Occup Environ Health; 2021 Nov; 94(8):1877-1888. PubMed ID: 34410477
[TBL] [Abstract][Full Text] [Related]
19. Environmental and biological monitoring of antineoplastic drugs in four workplaces in a Swedish hospital.
Hedmer M; Tinnerberg H; Axmon A; Jönsson BA
Int Arch Occup Environ Health; 2008 Jul; 81(7):899-911. PubMed ID: 18066576
[TBL] [Abstract][Full Text] [Related]
20. Sampling and mass spectrometric analytical methods for five antineoplastic drugs in the healthcare environment.
Pretty JR; Connor TH; Spasojevic I; Kurtz KS; McLaurin JL; B'Hymer C; Debord DG
J Oncol Pharm Pract; 2012 Mar; 18(1):23-36. PubMed ID: 21183556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
